Publication: 3732

Publication: 3732

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab versus Avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).

DOI

URL

Google Scholar

Citation:: J Clin Oncol vol 40 (16_suppl) TPS4607

Meeting Instance:: ASCO 2022
Year:: 2022
Type:: Abstract
Sub type:: Poster General
Funding:: NCTN
Endpoint:: No-Endpoint
Analysis:: Trial-Description-Only
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: GU
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, U24 CA196171, U10CA180863 (CCTG)

Corr. Author:
Authors:: Shilpa Gupta Matthew D. Galsky Michael J. Morris Karla V. Balman Ronald Chen Timothy M. Chan Laurent Dercle Tareq Al-Baghdadi Srikala Sridhar Aihua Edward Yen Petros Grivas Shiva Baghaie Alan Tan Jonathan E. Rosenberg

Networks:: KANSAS, LAPS-NY016, LAPS-TN008, MCRC, NY021, OH027

Study: Alliance-A032001
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: